Benzinga · Feb 26, 2026
AL
NASDAQ · ALKS
Alkermes plc
Healthcare · Biotechnology
$46.10
Down-$0.78 (-1.66%)
Updated Sep 5, 2026, 7:57 AM
SID Score
7.1/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.97B
- P/E ratio
- 20.51
- Dividend yield
- 0.00%
- 52-week range
- $26.40 – $55.67
- Volume
- 1.06M
- Avg. volume
- 1.92M
Price performance
ALKS price history
1M range · 21 trading sessions · Daily adjusted prices
ALKS closed at $46.10 after 21 trading sessions, down 6.24% for the selected period.
- Last close
- $46.10
- Period change
- -6.24%
- Period low
- $46.10
- Period high
- $50.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $46.14 | $46.93 | $45.80 | $46.10 | 1.06M |
| Sep 3, 2026 | $48.01 | $48.29 | $46.71 | $46.88 | 974.51K |
| Sep 2, 2026 | $47.70 | $48.735 | $46.68 | $47.72 | 1.57M |
| Sep 1, 2026 | $47.00 | $47.335 | $46.65 | $47.20 | 1.35M |
| Aug 31, 2026 | $47.25 | $47.56 | $46.46 | $46.99 | 1.44M |
| Aug 28, 2026 | $48.82 | $48.82 | $47.2501 | $47.41 | 1.43M |
| Aug 27, 2026 | $48.72 | $49.33 | $48.10 | $48.90 | 2.12M |
| Aug 26, 2026 | $49.23 | $49.35 | $48.46 | $49.16 | 660.88K |
| Aug 25, 2026 | $48.935 | $49.58 | $48.87 | $49.21 | 1.13M |
| Aug 24, 2026 | $48.05 | $49.03 | $47.64 | $48.87 | 1.3M |
| Aug 21, 2026 | $48.05 | $48.67 | $47.33 | $48.33 | 939.64K |
| Aug 20, 2026 | $49.37 | $49.8618 | $47.93 | $48.02 | 1.64M |
| Aug 19, 2026 | $51.26 | $51.29 | $50.0796 | $50.18 | 1.54M |
| Aug 18, 2026 | $50.10 | $50.42 | $49.46 | $49.48 | 970.92K |
| Aug 17, 2026 | $48.895 | $50.0762 | $48.62 | $49.85 | 764.04K |
| Aug 14, 2026 | $49.37 | $50.02 | $48.65 | $49.06 | 1.27M |
| Aug 13, 2026 | $51.66 | $51.66 | $49.2104 | $49.45 | 1.55M |
| Aug 12, 2026 | $49.22 | $50.53 | $48.50 | $50.28 | 1.32M |
| Aug 11, 2026 | $49.92 | $50.135 | $48.97 | $49.21 | 1.37M |
| Aug 10, 2026 | $48.39 | $49.81 | $48.39 | $49.40 | 1.51M |
| Aug 7, 2026 | $49.05 | $49.90 | $48.67 | $49.17 | 1.11M |
Latest ALKS news
The latest Smart Investors Daily articles mentioning ALKS.
Stock researchCompany · Overview
ALKS research
Overview
Company profile and research snapshot.
Company profile
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $46.00
- Implied upside
- —
- Analysts
- 23
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 29, 2026 | JP Morgan | Neutral | — |
| Jul 29, 2026 | Baird | Outperform | — |
| Jul 28, 2026 | Piper Sandler | Overweight | — |
| Jul 20, 2026 | Stifel | Buy | — |
| Jul 13, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 26, 2026
Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $43
Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $37 to $43.
Benzinga · Feb 26, 2026
RBC Capital Maintains Outperform on Alkermes, Lowers Price Target to $45
RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Outperform and lowers the price target from $47 to $45.
SeekingAlpha · Feb 25, 2026
Alkermes plc 2025 Q4 - Results - Earnings Call Presentation
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
